Can research concerning mushroom extract supplementation on pregnant women be permitted under Subpart B?

Research concerning mushroom extract supplementation on pregnant women can be permitted under Subpart B if the research may benefit both the mother and the fetus. This aligns with ethical guidelines that allow certain types of research involving vulnerable populations, including pregnant women, when there is a prospect of direct benefit. The justification for permitting this research is rooted in the understanding that if there are potential health benefits to both the mother and the fetus, the ethical considerations may support the conduction of the study under strict oversight and safety protocols.

Additional safeguards are typically in place to ensure the safety of both parties involved, which means that researchers must demonstrate that the potential benefits outweigh any risks to the participants. This is an important aspect of conducting research ethically and responsibly, especially when it involves populations that may be more vulnerable to risks.

While other options suggest absolute prohibitions or conditions based on minimal risk, they overlook the possibility of conducting research that can directly benefit both the mother and fetus, especially with adequate oversight and ethical review in place.